- Home
- CMCM vs PBYI Comparison
CMCM vs PBYI Comparison
Compare CMCM & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMCM
- PBYI
- Stock Information
- Founded
- CMCM 2009
- PBYI 2010
- Country
- CMCM China
- PBYI United States
- Employees
- CMCM N/A
- PBYI N/A
- Industry
- CMCM Computer Software: Prepackaged Software
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- CMCM Technology
- PBYI Health Care
- Exchange
- CMCM Nasdaq
- PBYI Nasdaq
- Market Cap
- CMCM 127.6M
- PBYI 138.4M
- IPO Year
- CMCM 2014
- PBYI N/A
- Fundamental
- Price
- CMCM $3.80
- PBYI $2.91
- Analyst Decision
- CMCM
- PBYI Strong Buy
- Analyst Count
- CMCM 0
- PBYI 1
- Target Price
- CMCM N/A
- PBYI $7.00
- AVG Volume (30 Days)
- CMCM 15.7K
- PBYI 280.0K
- Earning Date
- CMCM 06-06-2025
- PBYI 05-08-2025
- Dividend Yield
- CMCM N/A
- PBYI N/A
- EPS Growth
- CMCM N/A
- PBYI 143.51
- EPS
- CMCM N/A
- PBYI 0.77
- Revenue
- CMCM $110,544,725.00
- PBYI $232,668,000.00
- Revenue This Year
- CMCM $14.27
- PBYI N/A
- Revenue Next Year
- CMCM $39.26
- PBYI N/A
- P/E Ratio
- CMCM N/A
- PBYI $3.78
- Revenue Growth
- CMCM 20.52
- PBYI 2.67
- 52 Week Low
- CMCM $3.02
- PBYI $2.23
- 52 Week High
- CMCM $6.78
- PBYI $5.20
- Technical
- Relative Strength Index (RSI)
- CMCM 45.39
- PBYI 44.50
- Support Level
- CMCM $3.65
- PBYI $2.88
- Resistance Level
- CMCM $3.90
- PBYI $3.14
- Average True Range (ATR)
- CMCM 0.14
- PBYI 0.16
- MACD
- CMCM 0.05
- PBYI 0.00
- Stochastic Oscillator
- CMCM 42.86
- PBYI 11.36
About CMCM Cheetah Mobile Inc. each representing fifty (50)
Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.